A phase II study of temozolomide in hormone-refractory prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 6, 2000, Pages 509-512

  Van Brussel, Jérôme P ^a   Busstra, Martijn B ^a   Lang, Margreet S ^b   Catsburg, Tilly ^c   Schröder, Fritz H ^a   Mickisch, Gerald H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NONE

Author keywords

Chemotherapy; Efficacy; Prostate cancer; Safety; Temozolomide

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TEMOZOLOMIDE;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; THROMBOCYTOPENIA; VOMITING;

EID: 0034024467     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051027     Document Type: Article

References (8)

1. 1. Wingo PA, Tong T, Bolden S (1995) Cancer statistics. CA Cancer J Clin 45: 8
2. 2. Kreis W (1995) Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 13: 296
3. 3. Cersosimo RJ, Carr D (1996) Prostate cancer: current and evolving strategies. Am J Health Syst Pharm 53: 381
4. 4. Moore MJ, Tannock IF (1996) Overview of Canadian trials in hormonally resistant prostate cancer. Semin Oncol 23: 15
5. 5. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756
6. 6. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846
7. 7. Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG (1984). Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem 27: 196
8. 8. Gehan EA (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346